Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naive Adults

Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naive Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2018

At a glance

  • Drugs GSK 257049 (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Feb 2018 Results of pooled analysis of this and other five phase II studies assessing relationship between HLA allele groups and RTS,S-mediated protection in controlled human malaria infections, published in the Vaccine.
    • 13 Jun 2016 Primary endpoint has been met. (Occurrence of P. falciparum parasitemia in the 0, 1, 2-month group), as per an article published in the Journal of Infectious Diseases.
    • 13 Jun 2016 Primary endpoint has been met. (Occurrence of Plasmodium falciparum parasitemia in the delayed fractional dose group), as per an article published in the Journal of Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top